CD28 and arthritic joint disease: Leung et al. [35] administered bovine type II collagen intradermally on days 0 and 21 to mice to create arthritis, then from the 21st day, 14 days of intraperitoneal 40 mg/kg simvastatin was given and this agent was seen to have suppressed the collagen-specific Th-1 humoral and cellular immune response, reduced anti-CD3 and anti-CD28 proliferation and inhibited IFN-γ expression from mononuclear cells.